Experience

BioNTech Announces Global Collaboration Agreement With Bristol Myers Squibb

June 3, 2025

Cooley advised BioNTech SE, a global biotechnology company pioneering next-generation immunotherapies, on its global co-development and co-commercialization collaboration agreement with Bristol Myers Squibb for BioNTech’s antibody candidate BNT327. The transaction includes a $1.5 billion upfront payment and $2 billion total in noncontingent anniversary payments through 2028.

Read more

Related contacts

Kenneth Krisko
Partner, Reston
J. Brian Stalter
Special Counsel, New York
John Forrest
Associate, Boston
Arda Can Tekin
Associate, New York
Megan Browdie
Partner, Washington, DC
David Burns
Special Counsel, Washington, DC
Jonas Koponen
Partner, Brussels
Rachel Thorn
Of counsel, New York
Eric Blanchard
Partner, Boston
Christopher Kimball
Partner, Washington, DC
Joe Sandys
Special Counsel, London
Natasha Leskovsek
Of Counsel, Washington, DC
Navya Dasari
Associate, New York
Douglas Lyles
Senior Research Services & Access Analyst

Related Practices & Industries

Takara Bio Announces Acquisition of Curio Bioscience

January 15, 2025

Cooley advised Takara Bio, a global biotechnology and life sciences company headquartered in Shiga, Japan, on its acquisition of Curio Bioscience, a pioneering company in the field of spatial genomics.

Read more

Related contacts

Laura M. Medina
Partner, Colorado
Charity Williams
Partner, San Diego
Meredith Klionsky
Special Counsel, Washington, DC
John Forrest
Associate, Boston
Jeff Gutkin
Partner, San Francisco
Jonathan Rivinus
Partner, Colorado
David Walsh
Senior Counsel, Reston
Mark Windfeld-Hansen
Senior Counsel, Palo Alto
Bryan Berman
Special Counsel, Colorado
Stacey A. Bradford
Special Counsel, Washington, DC
Stefan Cohen
Associate, New York
Eileen Leman
Associate, Los Angeles
Patricia Myers
Paralegal Specialist, Colorado

Related Practices & Industries

Poseida Therapeutics Announces Agreement to Be Acquired by Roche for up to $1.5 Billion

November 26, 2024

Cooley advised Poseida Therapeutics, a clinical-stage allogeneic cell therapy and genetic medicines company advancing differentiated nonviral treatments for patients with cancer, autoimmune and rare diseases, on its merger agreement to be acquired by Roche at a price of $9 per share in cash at closing, plus a non-tradable contingent value right to receive up to an aggregate of $4 per share in cash, payable upon achievement of specified milestones. The price payable at closing represents a total equity value of up to $1.5 billion and a premium of approximately 215% to Poseida’s closing share price on November 25, 2024. Cooley previously represented Poseida in its initial public offering, equity and debt transactions, and collaboration agreements, including its collaboration agreement with Roche.

Read more

Related contacts

Rowook Park
Partner, San Diego
Barbara Borden
Senior Counsel, San Diego
Julia Kim
Special Counsel, New York
Rajdeep Roger Bains
Associate, San Diego
Josh Himmelstern
Associate, San Diego
Elaine Huang
Associate, Palo Alto
Anne Luquette
Associate, San Francisco
Allie Pilmer
Associate, San Diego
Tom Coll
Partner, San Diego
Kenneth Krisko
Partner, Reston
Edmond Lay
Partner, San Diego
John Forrest
Associate, Boston
Jenny Ge
Associate, Santa Monica
Peter Adams
Partner, San Diego
Michael Bergmann
Partner, Washington, DC
Megan Browdie
Partner, Washington, DC
Ross Eberly
Partner, Santa Monica
Todd Gluth
Partner, San Diego
Christopher Kimball
Partner, Washington, DC
Alessandra Murata
Partner, Palo Alto
Jeffrey J. Tolin
Partner, New York
Robert Eisenbach
Of Counsel, San Francisco
Maricel Mojares-Moore
Special Counsel, San Francisco
Dillon Martinson
Special Counsel, Washington, DC
Stella Sarma
Partner, Brussels
Natasha Leskovsek
Of Counsel, Washington, DC
Alexandria Ashour
Associate, San Diego
Navya Dasari
Associate, New York
Sara Kim
Associate, Los Angeles
Nicollette R. Kirby
Associate, Washington, DC
Allison Kutner
Associate, New York
Calvin Lee
Associate, New York
Calvin Lee
Associate, New York
Breanna Qin
Associate, Palo Alto
Shelby Saunders
Associate, New York
Shaun (Tianjie) Wang
Associate, New York
Colleen R. Wellington-Caban
Associate, Washington, DC
Jack Whitaker
Associate, San Diego
Anna Anderson
Paralegal Specialist, London
Novak Topalovic
Associate, San Diego

Related Practices & Industries

Aclaris Therapeutics Announces Global License Agreement With Biosion, $80 Million Private Placement

November 18, 2024

Cooley advised Aclaris Therapeutics (Nasdaq: ACRS), a clinical-stage biopharmaceutical company developing novel drug candidates for immuno-inflammatory diseases, on its exclusive license agreement with Biosion and $80 million private placement.

Read more

Related contacts

Mark Ballantyne
Partner, Reston
Kenneth Krisko
Partner, Reston
Brian Leaf
Partner, Reston
J. Brian Stalter
Special Counsel, New York
Ruomu Li
Partner, Shanghai
David Brinton
Associate, Washington, DC
Arjan Ganji
Associate, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
Daniel I. Goldberg
Partner, New York
Christopher Kimball
Partner, Washington, DC
Aaron Pomeroy
Partner, Colorado
Francis Wheeler
Senior Counsel, Colorado
Rebecca Ross
Special Counsel, Washington, DC
John Forrest
Associate, Boston
Zack Gong
Associate, Shanghai
Michael Shen
Special Counsel, Shanghai
Robin K. Lee
Paralegal Specialist, Colorado

Related Practices & Industries

Geron Corporation Announces up to $375 Million in Funding With Royalty Pharma and Pharmakon Advisors

November 7, 2024

Cooley advised Geron Corporation (Nasdaq: GERN), a commercial-stage biopharmaceutical company aiming to change lives by changing the course of blood cancer, on its up to $375 million in synthetic royalty and debt financings with Royalty Pharma and Pharmakon Advisors.

Read more

Related contacts

Mischi a Marca
Partner, San Francisco
Shimeng Cheng
Special Counsel, San Francisco
Addison Pierce
Partner, Chicago
Chadwick Mills
Partner, San Francisco
Dr. Jon Cousin
Partner, Washington, DC
Xander Lee
Partner, Santa Monica
Jennifer Raab
Partner, Palo Alto
Ryan Blair
Partner, San Diego
Phil Mitchell
Partner, New York
Francis Wheeler
Senior Counsel, Colorado
Andrew Epstein
Special Counsel, Seattle
Marina Remennik
Special Counsel, Palo Alto
Karen Tsai
Special Counsel, Washington, DC
Natasha Leskovsek
Of Counsel, Washington, DC
John Forrest
Associate, Boston
Gary Warren Hunt III
Associate, Washington, DC
Xueqing Li
Associate, San Francisco
Leo Spicer-Phelps
Partner, London
Dr. Jason Valentine
Associate, Washington, DC
Charles A. Watkins II
Associate, Santa Monica
Jennifer Fitzpatrick
Paralegal Specialist, Washington, DC
Chris Rhem
Paralegal Specialist, San Francisco

Related Practices & Industries

View more

Admissions and credentials

District of Columbia

Maryland

US Patent and Trademark Office

Not admitted to practice in Massachusetts

Not admitted to practice in Virginia